The Treatment of Hypertension in Adult Patients With Diabetes

Arauz-Pacheco, Carlos; Parrott, Marian A.; Raskin, Philip

doi:10.2337/diacare.25.1.134

Cited by 327Blood Pressure and Hypertension StudiesChronic Kidney Disease and DiabetesDiabetes, Cardiovascular Risks, and Lipoproteins

The Treatment of Hypertension in Adult Patients With Diabetes

Open access

Arauz-Pacheco, Carlos, Parrott, Marian A., Raskin, Philip·2002·Diabetes Care

DOI 10.2337/diacare.25.1.134

Open this paper in CoChat — free account Open PDF

Abstract

Hypertension is an extremely common comorbidity of diabetes, affecting 20–60% of people with diabetes. Hypertension is also a major risk factor for cardiovascular events, such as myocardial infarction and stroke, as well as for microvascular complications, such as retinopathy and nephropathy. Cardiovascular disease is the most costly complication of diabetes and is the cause of 86% of deaths in persons with diabetes (1). However, until recently, little research had been done specifically in patients with diabetes and hypertension. In reviewing the literature on diabetes and hypertension, the authors searched MEDLINE for English language articles using keywords “hypertension,” “diabetes mellitus,” “diabetic nephropathy,” and “coronary artery disease/prevention” starting from 1966. Before 1996, most available data come from secondary analysis from studies done in the general population of people with hypertension, observing a subset with diabetes. Recent studies have demonstrated the effectiveness of blood pressure treatment versus placebo in reducing complications of diabetes (2,3), helped to define the optimal level of blood pressure control (4,5,6), and compared treatment strategies based on different drug classes (7,8,9,10,11,12,13). The results of these studies support an aggressive approach to the diagnosis and treatment of hypertension in patients with diabetes in order to substantially reduce the incidence of both macrovascular and microvascular complications. ### Definition of hypertension in diabetic populations Epidemiological studies and therapeutic trials have often used different criteria to define hypertension in diabetic patients. Studies in the general population indicate an increased risk of cardiovascular disease with an increase in the level of blood pressure. Thus, an increase in diastolic or systolic blood pressure of 5 mmHg is associated with a concomitant increase in cardiovascular disease of 20–30% (14). Studies in diabetic populations have shown a markedly higher frequency of the progression of diabetic retinopathy …

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/diacare.25.1.134

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Weight loss of 1 kilogram has been reported to decrease mean arterial blood pressure by approximately 1 mm Hg.
“weight loss of 1 kilogram has been reported to decrease mean arterial blood pressure by approximately 1 mm Hg.”
From The case for low carbohydrate diets in diabetes management (2005) · cites this paper as [74]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386 · see citing works
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · see citing works
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
(1998) · BMJ · doi:10.1136/bmj.317.7160.703 · Cited by 6,683 · see citing works
The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.157.21.2413 · Cited by 6,345 · see citing works
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · see citing works
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728 · see citing works
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394 · see citing works
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803 · see citing works
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491 · see citing works
Blood pressure, stroke, and coronary heart disease *1Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias
MACMAHON, S. (1990) · The Lancet · doi:10.1016/0140-6736(90)90878-9 · Cited by 4,253 · cited 1× · see citing works
“Thus, an increase in diastolic or systolic blood pressure of 5 mmHg is associated with a concomitant increase in cardiovascular disease of 20–30% (14).”
Background
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy
(2000) · The Lancet · doi:10.1016/s0140-6736(99)12323-7 · Cited by 3,179 · see citing works
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873 · see citing works
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,527 · see citing works
Insulin Resistance in Essential Hypertension
Ferrannini, E., Buzzigoli, G., Bonadonna, R., Giorico, M. A., Oleggini, M., Graziadei, L., Pedrinelli, R., Brandi, L., & Bevilacqua, S. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708063170605 · Cited by 2,344 · see citing works
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study
Adler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133 · see citing works
Untitled work
(2000) · PubMed · Cited by 2,095 · see citing works
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
Hansson, L., Lindholm, L. H., NISKANEN, L. K., Lanke, J., Hedner, T., Niklason, A., LUOMANMÄKI, K., Dahlöf, B., Fairé, U. D., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 1,991 · see citing works
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials
(2000) · The Lancet · doi:10.1016/s0140-6736(00)03307-9 · Cited by 1,790 · see citing works
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B., et al. (1998) · BMJ · doi:10.1136/bmj.317.7160.713 · Cited by 1,784 · see citing works
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
Hansson, L., Lindholm, L. H., Ekbom, T., Dahlöf, B., Lanke, J., Scherstén, B., Wester, P.-O., Hedner, T., & Fairé, U. D. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10327-1 · Cited by 1,442 · see citing works
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 1,406 · see citing works
Preserving renal function in adults with hypertension and diabetes: A consensus approach
Bakris, G. L., Williams, M. E., Dworkin, L. D., Elliott, W. J., Epstein, M., Toto, R. D., Tuttle, K. R., Douglas, J. G., Hsueh, W. A., & Sowers, J. R. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.16225 · Cited by 1,399 · see citing works
Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
Brown, M. J., Palmer, C. R., Castaigne, A., de Leeuw, P. W., Mancia, G., Rosenthal, T., & Ruilope, L. M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02527-7 · Cited by 1,206 · see citing works
Nifedipine
Furberg, C. D., Psaty, B. M., & Meyer, J. V. (1995) · Circulation · doi:10.1161/01.cir.92.5.1326 · Cited by 1,179 · see citing works
The Effect of Nisoldipine as Compared with Enalapril on Cardiovascular Outcomes in Patients with Non-Insulin-Dependent Diabetes and Hypertension
Estacio, R. O., Jeffers, B. W., Hiatt, W. R., Biggerstaff, S. L., Gifford, N., & Schrier, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803053381003 · Cited by 1,158 · see citing works
Effect of Insulin and Glucose Infusions on Sympathetic Nervous System Activity in Normal Man
Rowe, J. W., Young, J. B., Minaker, K. L., Stevens, A. L., Pallotta, J., & Landsberg, L. (1981) · Diabetes · doi:10.2337/diab.30.3.219 · Cited by 1,143 · see citing works
The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.
DeFronzo, R. A., Cooke, C. R., Andres, R., Faloona, G. R., & Davis, P. J. (1975) · Journal of Clinical Investigation · doi:10.1172/jci107996 · Cited by 1,113 · see citing works
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study
Mogensen, C. E., Neldam, S., Tikkanen, I., Oren, S., Viskoper, R. J., Watts, R. W., & Cooper, M. E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1440 · Cited by 1,026 · see citing works
Effect of Diuretic-Based Antihypertensive Treatment on Cardiovascular Disease Risk in Older Diabetic Patients With Isolated Systolic Hypertension
Curb, J. D. (1996) · JAMA · doi:10.1001/jama.1996.03540230036032 · Cited by 955 · see citing works
Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension
Tuomilehto, J. O., Rastenytė, D., Birkenhäger, W. H., Thijs, L., Antikaínen, R., Bulpitt, C. J., FLETCHER, A. E., Forette, F., Goldhaber, A., Palatini, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400902 · Cited by 932 · see citing works
Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance.
Laakso, M., Edelman, S. V., Brechtel, G., & Baron, A. D. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114644 · Cited by 930 · see citing works
Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study
Hansson, L., Hedner, T., Lund‐Johansen, P., Kjeldsen, S. E., Lindholm, L. H., Syvertsen, J. O., Lanke, J., Fairé, U. D., Dahlöf, B., & Karlberg, B. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02526-5 · Cited by 903 · see citing works
Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM
Tatti, P., Pahor, M., Byington, R. P., Mauro, P. D., Guarisco, R., Strollo, G., & Strollo, F. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.597 · Cited by 843 · see citing works
Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy
Mogensen, C. E. (1982) · BMJ · doi:10.1136/bmj.285.6343.685 · Cited by 763 · see citing works
Phenylpropanolamine and the Risk of Hemorrhagic Stroke
Kernan, W. N., Viscoli, C. M., Brass, L. M., Broderick, J. P., Brott, T. G., Feldmann, E. G., Morgenstern, L. B., Wilterdink, J. L., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432501 · Cited by 755 · see citing works
Untitled work
(2000) · PubMed · Cited by 691 · see citing works
Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Davis, B. R. (1996) · American Journal of Hypertension · doi:10.1016/0895-7061(96)00037-4 · Cited by 595 · see citing works
Effect of Reduced Dietary Sodium on Blood Pressure
Midgley, J. (1996) · JAMA · doi:10.1001/jama.1996.03530440070039 · Cited by 544 · see citing works
Effect of antihypertensive treatment on kidney function in diabetic nephropathy.
Parving, H., Andersen, A. R., Smidt, U. M., Hommel, E. E., Mathiesen, E. R., & Svendsen, P. A. (1987) · BMJ · doi:10.1136/bmj.294.6585.1443 · Cited by 534 · see citing works
Randomized trials of sodium reduction: an overview
Cutler, J., Follmann, D. A., & Allender, P. (1997) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/65.2.643s · Cited by 523 · see citing works
Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications
&NA;, &. (1993) · Journal of Hypertension · doi:10.1097/00004872-199303000-00012 · Cited by 491 · see citing works
Development and Progression of Renal Disease in Pima Indians with Non-Insulin-Dependent Diabetes Mellitus
Nelson, R. G., Bennett, P. H., Beck, G. J., Tan, M., Knowler, W. C., Mitch, W. E., Hirschman, G. H., & Myers, B. D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611283352203 · Cited by 471 · see citing works
Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria.
Mathiesen, E. R., Hommel, E. E., Giese, J., & Parving, H. ‐. (1991) · BMJ · doi:10.1136/bmj.303.6794.81 · Cited by 465 · see citing works
Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy
Bakris, G. L., Copley, J. B., Vicknair, N., Sadler, R., & Leurgans, S. (1996) · Kidney International · doi:10.1038/ki.1996.480 · Cited by 417 · see citing works
Smoking and diabetes
Haire-Joshu, D., Glasgow, R. E., & Tibbs, T. L. (1999) · Diabetes Care · doi:10.2337/diacare.22.11.1887 · Cited by 381 · see citing works
Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria.
Marre, M., Châtellier, G., Leblanc, H., Guyene, T. T., Ménard, J., & Passa, P. (1988) · BMJ · doi:10.1136/bmj.297.6656.1092 · Cited by 372 · see citing works
Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension
Pollare, T., Lithell, H., Selinus, I., & Berne, C. (1988) · Diabetologia · doi:10.1007/bf00271585 · Cited by 354 · see citing works
Should All Patients with Type 1 Diabetes Mellitus and Microalbuminuria Receive Angiotensin-Converting Enzyme Inhibitors?
The ACE Inhibitors in Diabetic Nephropathy Trialist Group* (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-5-200103060-00009 · Cited by 338 · see citing works
Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy.
Parving, H. ‐., Hommel, E. E., & Smidt, U. (1988) · BMJ · doi:10.1136/bmj.297.6656.1086 · Cited by 330 · see citing works
Pharmacology of Antihypertensive Drugs.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-4-650_9 · Cited by 325 · see citing works
Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · Cited by 302 · see citing works
Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
UK Prospective Diabetes Study Group (1998) · BMJ · doi:10.1136/bmj.317.7160.720 · Cited by 301 · see citing works
Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data
Chaturvedi, N. (2001) · UCL Discovery (University College London) · Cited by 299 · see citing works
Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy
Andersen, S., Tarnow, L., Rossing, P. R., Hansen, B. V., & Parving, H. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00880.x · Cited by 287 · see citing works
Standards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s33 · Cited by 262 · see citing works
Relationship Between Blood Pressure and Urinary Albumin Excretion in Development of Microalbuminuria
Mathiesen, E. R., Rønn, B. B., Jensen, T. J., Storm, B., & Deckert, T. (1990) · Diabetes · doi:10.2337/diab.39.2.245 · Cited by 251 · see citing works
Efficacy and Safety of Sibutramine in Obese White and African American Patients With Hypertension
McMahon, F. G., Fujioka, K., Singh, B. N., Mendel, C. M., Rowe, E., Rolston, K., Johnson, F. K., & Mooradian, A. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2185 · Cited by 246 · see citing works
Prevalence of Diabetic Complications in Relation to Risk Factors
Knuiman, M. W., Welborn, T. A., McCann, V. J., Stanton, K. G., & Constable, I. J. (1986) · Diabetes · doi:10.2337/diab.35.12.1332 · Cited by 242 · see citing works
Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy
Lacourcière, Y., Bélanger, A., Godin, C., Hallé, J., Ross, S. A., Wright, N., & Marion, J. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00224.x · Cited by 226 · see citing works
The Progressive Cost of Complications in Type 2 Diabetes Mellitus
Brown, J. B., Pedula, K. L., & Bakst, A. W. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.16.1873 · Cited by 216 · see citing works
Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in Type 1 (insulin-dependent) diabetes mellitus
Feldt‐Rasmussen, B., Mathiesen, E. R., Deckert, T., Giese, J., Christensen, N. J., Bent-Hansen, L., & Nielsen, M. D. (1987) · Diabetologia · doi:10.1007/bf00277316 · Cited by 202 · see citing works
Relation of Ocular and Systemic Factors to Survival in Diabetes
Klein, R. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390020016004 · Cited by 200 · see citing works
Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group.
(1991) · BMJ · doi:10.1136/bmj.302.6770.210 · Cited by 196 · see citing works
Reduction in blood pressure with a low sodium, high potassium, high magnesium salt in older subjects with mild to moderate hypertension
Geleijnse, J. M., Witteman, J. C. M., Bak, A. A. A., den Breeijen, J. H., & Grobbee, D. E. (1994) · BMJ · doi:10.1136/bmj.309.6952.436 · Cited by 185 · see citing works
Sodium, renin, aldosterone, catecholamines, and blood pressure in diabetes mellitus
de Châtel, R., Weidmann, P., Flammer, J., Ziegler, W. H., Beretta-Piccoli, C., Vetter, W., & Reubi, F. C. (1977) · Kidney International · doi:10.1038/ki.1977.132 · Cited by 182 · see citing works
Long-Term Effect of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic Nephropathy
Nielsen, F. S., Rossing, P. R., Gall, M.-A., Skøtt, P., Smidt, U., & Parving, H. (1997) · Diabetes · doi:10.2337/diab.46.7.1182 · Cited by 182 · see citing works
Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine.
Heal, D. J., Aspley, S., Prow, M. R., Jackson, H. C., Martin, K. F., & Cheetham, S. (1998) · PubMed · Cited by 178 · see citing works
Mortality Trends in Type 1 Diabetes
Nishimura, R., LaPorte, R. E., Dorman, J. S., Tajima, N., BECKER, D. J., & Orchard, T. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.5.823 · Cited by 170 · see citing works
[Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials].
Schillaci, G., & Vaudo, G. (2001) · PubMed · Cited by 169 · see citing works
Effects of Diltiazem or Lisinopril on Massive Proteinuria Associated with Diabetes Mellitus
Bakris, G. L. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-9-707 · Cited by 166 · see citing works
Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group
Curb, J. D. (1996) · JAMA · doi:10.1001/jama.276.23.1886 · Cited by 161 · see citing works
Effects of Cilazapril and Amlodipine on Kidney Function in Hypertensive NIDDM Patients
Velussi, M., Brocco, E., Frigato, F., Zolli, M., Muollo, B., Maioli, M., Carraro, A., Tonolo, G., Fresu, P., Cernigoi, A. M., et al. (1996) · Diabetes · doi:10.2337/diab.45.2.216 · Cited by 157 · see citing works
Effect of Calcium Channel or β-Blockade on the Progression of Diabetic Nephropathy in African Americans
Bakris, G. L., Mangrum, A. J., Copley, J. B., Vicknair, N., & Sadler, R. (1997) · Hypertension · doi:10.1161/01.hyp.29.3.744 · Cited by 147 · see citing works
Excess Mortality Associated With Diuretic Therapy in Diabetes Mellitus
Warram, J. H. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400070114014 · Cited by 145 · see citing works
Risk Factors for Progression of Background Retinopathy in Long-Standing IDDM
Janka, H. U., Warram, J. H., Rand, L. I., & Królewski, A. S. (1989) · Diabetes · doi:10.2337/diab.38.4.460 · Cited by 144 · see citing works
Blood pressure and metabolic control as risk factors for nephropathy in Type 1 (insulin-dependent) diabetes
Hasslacher, C., Stech, W., Wahl, P. M., & Ritz, E. (1985) · Diabetologia · doi:10.1007/bf00276992 · Cited by 143 · see citing works
Losartan and Low-Dose Hydrochlorothiazide in Patients With Essential Hypertension
MacKay, J. H. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440030072009 · Cited by 142 · see citing works
Diabetic autonomic neuropathy and cardiovascular risk. Pittsburgh Epidemiology of Diabetes Complications Study III
Maser, R. E. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.150.6.1218 · Cited by 141 · see citing works
Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials
Midgley, J. (1996) · JAMA · doi:10.1001/jama.275.20.1590 · Cited by 134 · see citing works
The Effects of Weight Reduction on Blood Pressure in 301 Obese Patients
Schotte, D. E. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.1990.00040031701019 · Cited by 129 · see citing works
Newer Approaches to Antihypertensive Therapy
Epstein, M. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440160081011 · Cited by 129 · see citing works
Hyperkalemia as a Complication of Drug Therapy
Rimmer, J. M. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370050063011 · Cited by 128 · see citing works
Pharmacokinetic profile of ceftriaxone in man.
Patel, I. H., & Kaplan, S. A. (1984) · PubMed · Cited by 128 · see citing works
Exchangeable sodium and renin in hypertensive diabetic patients with and without nephropathy.
O’Hare, J. A., Ferriss, J. B., Brady, D., Twomey, B. M., & O’Sullivan, D. J. (1985) · Hypertension · doi:10.1161/01.hyp.7.6_pt_2.ii43 · Cited by 124 · see citing works
Treatment of Hypertension: Drug Therapy
Lee, B. H. (1997) · Korean Circulation Journal · doi:10.4070/kcj.1997.27.3.350 · Cited by 98 · see citing works
Aspects of Tolerability of Centrally Acting Antihypertensive Drugs
Webster, J., & Koch, H. (1996) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199627003-00007 · Cited by 87 · see citing works
Cellular ions in hypertension, insulin resistance, obesity, and diabetes
Resnick, L. M. (1992) · Journal of the American Society of Nephrology · doi:10.1681/asn.v34s78 · Cited by 86 · see citing works
A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM
Harper, R., Ennis, C. N., Heaney, A., Sheridan, B., Gormley, M., Atkinson, A. B., Johnston, G., & Bell, P. M. (1995) · Diabetologia · doi:10.1007/s001250050363 · Cited by 84 · see citing works
Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria
Mathiesen, E. R., Rønn, B. B., Jensen, T., et al. (1990) · Diabetes · doi:10.2337/diabetes.39.2.245 · Cited by 82 · see citing works
A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients
Lender, D. (1999) · American Journal of Hypertension · doi:10.1016/s0895-7061(98)00259-3 · Cited by 79 · see citing works
Prevalence of diabetic complications in relation to risk factors
Knuiman, M. W., Welborn, T. A., Vj, M., et al. (1986) · Diabetes · doi:10.2337/diabetes.35.12.1332 · Cited by 79 · see citing works
Body weight, sodium intake and blood pressure
Staessen, J. A., Fagard, R. H., Lijnen, P. J., & Amery, A. K. P. C. (1989) · Journal of Hypertension · doi:10.1097/00004872-198902001-00006 · Cited by 76 · see citing works
Cost-effectiveness of the Lower Treatment Goal (of JNC VI) for Diabetic Hypertensive Patients
Elliott, W. J., Weir, D. R., & Black, H. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.9.1277 · Cited by 73 · see citing works
Controlled Trial of Losartan Given Concomitantly with Different Doses of Hydrochlorothiazide in Hypertensive Patients
Ruilope, L. M., Simpson, R. L., Toh, J., Arcuri, K. E., Goldberg, A. I., & Sweet, C. S. (1996) · Blood Pressure · doi:10.3109/08037059609062104 · Cited by 73 · see citing works
Implications of discontinuation of doxazosin arm of ALLHAT
Messerli, F. H. (2000) · The Lancet · doi:10.1016/s0140-6736(00)00092-1 · Cited by 69 · see citing works
The cost‐effectiveness of treating hypertension in elderly people—an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension)
Johannesson, M., Dahlöf, B., Lindholm, L. H., Ekbom, T., Hansson, L., Odén, A., Scherstén, B., Wester, P. O., & Jönsson, B. (1993) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1993.tb00749.x · Cited by 69 · see citing works
Epidemiologic Review of the Calcium Channel Blocker Drugs
Kizer, J. R., & Kimmel, S. E. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.9.1145 · Cited by 65 · see citing works
Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patient. Enalapril for hypertensive diabetics
Prince, M. J. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.148.11.2363 · Cited by 61 · see citing works
Differences Between Nisoldipine and Lisinopril on Glomerular Filtration Rates and Albuminuria in Hypertensive IDDM Patients With Diabetic Nephropathy During the First Year of Treatment
Rossing, P. R., Tarnow, L., Boelskifte, S., Jensen, B. R., Nielsen, F. S., & Parving, H. (1997) · Diabetes · doi:10.2337/diab.46.3.481 · Cited by 59 · see citing works
Essential Hypertension Is Associated With Decreased Insulin Clearance and Insulin Resistance
Lender, D., Arauz-Pacheco, C., ADAMS-HUET, B. A., & Raskin, P. (1997) · Hypertension · doi:10.1161/01.hyp.29.1.111 · Cited by 55 · see citing works
Self-citation
Beta-blockers in hypertensive and coronary heart disease
Goldstein, S. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.12.1267 · Cited by 55 · see citing works
Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes
Schneider, M., Lerch, M., Papiri, M., Buechel, P., Böhlen, L., Shaw, S., Risen, W., & Wiedmann, P. (1996) · Journal of Hypertension · doi:10.1097/00004872-199605000-00018 · Cited by 51 · see citing works
Risk factors for progression of background retinopathy in long-standing IDDM
Janka, H. U., Warram, J. H., Rand, L. I., et al. (1989) · Diabetes · doi:10.2337/diabetes.38.4.460 · Cited by 47 · see citing works
Metabolic disturbances in hypertension: results from the population study ‘ Men born in 1913’
Eriksson, H., Welin, L., Wilhelmsen, L., Larsson, B., Ohlson, L. ‐., Svärdsudd, K., & Tibblin, G. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00604.x · Cited by 45 · see citing works
Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients
Velussi, M., Brocco, E., Frigato, F., et al. (1996) · Diabetes · doi:10.2337/diabetes.45.2.216 · Cited by 45 · see citing works
Relation of ocular and systemic factors to survival in diabetes
Klein, R. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.2.266 · Cited by 44 · see citing works
Role of Alpha Adrenoceptors in Hypertension and in Anti hypertensive Drug Treatment
van Zwieten, P. A., Timmermans, P. B. M. W. M., & van Brummelen, P. (1984) · The American Journal of Medicine · doi:10.1016/s0002-9343(84)80033-9 · Cited by 40 · see citing works
Comorbidity of hypertension and diabetes: the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET)
Sowers, J. R. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00751-6 · Cited by 40 · see citing works
Pharmacologic and Therapeutic Differences Among Calcium Channel Antagonists: Profile of Mibefradil, a New Calcium Antagonist
Triggle, D. J. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00732-1 · Cited by 38 · see citing works
The cost‐effectiveness of a cardiovascular multiple‐risk‐factor intervention programme in treated hypertensive men
Johannesson, M., Agewall, S., Hartford, M., Hedner, T., & Fagerberg, B. (1995) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1995.tb01135.x · Cited by 32 · see citing works
Effects of Metoprolol on the Counter‐regulation and Recognition of Prolonged Hypoglycemia in Insulin‐dependent Diabetics
CLAUSEN‐SJÖBOM, N., LINS, P.-E. S., Adamson, U., Curstedt, T., & Hamberger, B. (1987) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1987.tb09929.x · Cited by 31 · see citing works
Long-term reduction of microalbuminuria after 3 years of angiotensin-converting enzyme inhibition by perindopril in hypertensive insulin-treated diabetic patients
Hermans, M. P., Brichard, S. M., Colin, I. M., Borgies, P., Ketelslegers, J., & Lambert, A. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90158-8 · Cited by 29 · see citing works
Diuretic Drugs
Lant, A. F. (1986) · Drugs · doi:10.2165/00003495-198600314-00006 · Cited by 29 · see citing works
Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components
Jh, M. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.3.278 · Cited by 28 · see citing works
Effects of Atenolol and Enalapril on Kidney Function in Hypertensive Diabetic Patients
Cesaris, R. D., Ranieri, G., Filitti, V., Andriani, A., & Bonfantino, M. V. (1993) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199308000-00006 · Cited by 27 · see citing works
Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy
Epstein, M. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.17.1969 · Cited by 26 · see citing works
The effects of weight reduction on blood pressure in 301 obese patients
Schotte, D. E. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.150.8.1701 · Cited by 23 · see citing works
Excess mortality associated with diuretic therapy in diabetes mellitus
Warram, J. H. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.151.7.1350 · Cited by 23 · see citing works
New Evidence on the Prevention of Cardiovascular Events in Hypertensive Patients with Type 2 Diabetes
Pahor, M., Psaty, B. M., & Furberg, C. D. (1998) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199800004-00004 · Cited by 22 · see citing works
Classification of ??-Lactamases from Branhamella catarrhalis in Relation to Penicillinases Produced by Other Bacterial Species
Labia, R., Barthélémy, M., Bouguénec, C. L., & Buu-Hoï, A. (1986) · Drugs · doi:10.2165/00003495-198600313-00011 · Cited by 22 · see citing works
Calcium antagonists and cardiovascular risk in diabetes
Parving, H. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00758-9 · Cited by 21 · see citing works
Calcium intake and blood pressure: epidemiology revisited.
Cd, M., & Me, R. (1995) · PubMed · Cited by 16 · see citing works
Calcium antagonists and the diabetic patient: a response to recent controversies
Poulter, N. R. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00757-7 · Cited by 15 · see citing works
Nitrendipine and enalapril in the treatment of diabetic hypertensive patients with microalbuminuria.
Piñol, C., Cobos, A., Cases, A., Esmatges, E., Soler, J., Closas, J., Pascual, R., & Planas, J. (1996) · PubMed · Cited by 15 · see citing works
Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease
Ferrari, R., Ceconi, C., Curello, S., Pepi, P., Mazzoletti, A., & Visioli, O. (1996) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00052511 · Cited by 14 · see citing works
Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment
Rossing, P., Tarnow, L., Boelskifte, S., et al. (1997) · Diabetes · doi:10.2337/diabetes.46.3.481 · Cited by 14 · see citing works
The calcium antagonist controversy: a posthumous commentary 1 1Modified from Grossman E, Messerli FH. Calcium antagonists in cardiovascular disease: a necessary controversy but an unnecessary panic. (Editorial.) Am J Med 1997;102:147–149; and from Messerli FH, Grossman E. Do calcium antagonists increase the risk for malignancies? (Editorial.) J Am Coll Cardiol 1998;31:809–810.
Messerli, F. H., & Grossman, E. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00756-5 · Cited by 12 · see citing works
Hyperkalemia as a complication of drug therapy
Rimmer, J. M. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.147.5.867 · Cited by 12 · see citing works
Smoking and Diabetes
American Diabetes Association (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s80 · Cited by 11 · see citing works
Dietary Factors and Blood Pressure Regulation
Moore, T. J., & McKnight, J. A. (1995) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30036-7 · Cited by 9 · see citing works
Forearm and finger hemodynamics, blood pressure control, and lipid changes in diabetic hypertensive patients treated with atenolol and prazosin
Kwan, C. M., Shepherd, A. M. M., Johnson, J. M., Taylor, W. F., & Brockway, B. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90131-9 · Cited by 8 · see citing works
New Evidence on the Prevention of Cardiovascular Events in Hypertensive Patients with Type 2 Diabetes
Pahor, M., Psaty, B. M., & Furberg, C. D. (1998) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199806322-00004 · Cited by 8 · see citing works
CHLORTHALIDONE-MODULATED VASCULAR RESPONSES TO VASODILATOR STIMULI IN DOCA-SALT HYPERTENSIVE RATS
Bissoli, N. S. (1996) · Pharmacological Research · doi:10.1006/phrs.1996.0008 · Cited by 7 · see citing works
A Comparison of the Hypotensive Effects of Captopril and Atenolol in the Treatment of Hypertension in Diabetic Patients
Elving, L. D., de Nobel, E., van Lier, H. J. J., & Thien, T. (1989) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1989.tb03334.x · Cited by 7 · see citing works
Critique of a biologic mechanism linking calcium antagonists to increased risk for cardiovascular events in diabetes
Mason, R. P., & Mason, P. E. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00754-1 · Cited by 6 · see citing works
Importance of Weight Loss and Sodium Restriction in the Treatment of Mild and Moderate Essential Hypertension
Krzesinski, J. M., Janssens, M., Vanderspeeten, F., & Rorive, G. L. (1993) · Acta Clinica Belgica · doi:10.1080/17843286.1993.11718314 · Cited by 5 · see citing works

Flagged first, then by citations

Sorted by citations

Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167 · see citing works
“Evidence is summarized in the following sections and reviewed in detail in the ADA technical reviews on hypertension (155), dyslipidemia (156), aspirin therapy (157), and smoking cessation (158) and in the American Heart Association (AHA)/ADA scientific statement on prevention of CVD in people with diabetes (159).”
Standards of Medical Care in Diabetes–2006
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s4 · Cited by 1,884 · see citing works
“Evidence is summarized in the following sections and reviewed in detail in the ADA technical reviews on hypertension (100), dyslipidemia (101), aspirin therapy (102), and smoking cessation (103) and the consensus statement on CHD in people with diabetes (104).”
Standards of Medical Care in Diabetes 2014
(2014) · Majmaah Journal of Health Sciences · doi:10.12816/0004790 · Cited by 1,478 · see citing works
Standards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377 · see citing works
“Evidence is summarized in the following sections and reviewed in detail in the ADA technical reviews on hypertension (125), dyslipidemia (126), aspirin therapy (127), and smoking cessation (128), and in the AHA/ ADA scientific statement on prevention of CVD in people with diabetes (129).”
Nowy rok, stare problemy, ale i nowe możliwości
Czupryniak, L. (2014) · Via Medica Journals · Cited by 1,192 · see citing works
Standards of Medical Care in Diabetes—2007
American Diabetes Association (2007) · Diabetes Care · doi:10.2337/dc07-s004 · Cited by 1,190 · see citing works
“Evidence is summarized in the following sections and reviewed in detail in the ADA technical reviews on hypertension (92), dyslipidemia (93), aspirin therapy (131), and smoking cessation (94) and the consensus statement on CHD in people with diabetes (95).”
Background
Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension: A Randomized Controlled Trial
Bakris, G. L., Fonseca, V., Katholi, R. E., McGill, J. B., Messerli, F. H., Phillips, R. A., Raskin, P., Wright, J. T., Oakes, R., Lukas, M. A., et al. (2004) · JAMA · doi:10.1001/jama.292.18.2227 · Cited by 792 · see citing works
“25 mg of carvedilol twice daily and 50 mg of metoprolol twice daily to a maximum dose of 25 mg and 200 mg twice daily, respectively, at 1- to 2-week intervals toward target BP levels for a total of 2 to 7 weeks.(10,18) Target systolic BP was 135 mm Hg or less for those participants with baseline of 140 to 179 mm Hg an…”
BackgroundSelf-citation
Diabetes and hypertension: a position statement by the American Diabetes Association
de Boer, I. H., Bangalore, S., Benetos, A., Davis, A. M., Michos, E. D., Muntner, P., Rossing, P., Zoungas, S., & Bakris, G. (2017) · Diabetes Care · doi:10.2337/dci17-0026 · Cited by 714 · see citing works
“However, results from trials in primary hypertension have shown a reduction in systolic blood pressure of ;5 mmHg and diastolic blood pressure of 2–3 mmHg with moderate sodium reduction (from a daily intake of 200 mmol [4,600 mg] to 100 mmol [2,300 mg] of sodium per day) (57).”
Background
Standards of Medical Care in Diabetes
(2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s15 · Cited by 684 · see citing works
Standards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s33 · Cited by 610 · see citing works
Diabetes mellitus and periodontal disease
Mealey, B. L., & Ocampo, G. L. (2007) · Periodontology 2000 · doi:10.1111/j.1600-0757.2006.00193.x · Cited by 565 · see citing works
“Initial pharmacological treatment includes drugs like angiotensin-converting enzyme inhibitors, a-adrenergic receptor blockers, low-dose thiazide diuretics, and bblockers (8).”
Background
Prevention of Heart Failure
Schocken, D. D., Benjamin, E. J., Fonarow, G. C., Krumholz, H. M., Levy, D. A., Mensah, G. A., Narula, J., Stuart‐Shor, E., Young, J. B., & Hong, Y. (2008) · Circulation · doi:10.1161/circulationaha.107.188965 · Cited by 548 · see citing works
Diabetic Retinopathy
Gardner, T. W., Antonetti, D. A., Barber, A. J., LaNoue, K. F., & Levison, S. W. (2002) · Survey of Ophthalmology · doi:10.1016/s0039-6257(02)00387-9 · Cited by 535 · see citing works
Treatment of Hypertension in Adults With Diabetes
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s80 · Cited by 509 · see citing works
Managing preexisting diabetes for pregnancy
Kitzmiller, J. L., Block, J. M., Brown, F. M., Catalano, P. M., Conway, D. L., Coustan, D. R., Gunderson, E. P., Herman, W. H., Hoffman, L. D., Inturrisi, M., et al. (2008) · Diabetes Care · doi:10.2337/dc08-9020 · Cited by 476 · see citing works
Initial management of glycemia in type 2 diabetes mellitus
Nathan, D. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp021106 · Cited by 359 · see citing works
Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Whelton, P. K. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1401 · Cited by 290 · see citing works
“Lowering BP may provide the most effective means to reduce the risk of CVD in patients with DM.(7,8) Agents that interfere with the renin-angiotensin system, especially angiotensin-converting enzyme inhibitors (ACEIs), have been recommended as first-step antihypertensive treatment in patients with DM and proteinuria.”
BackgroundInfluential
Hypertension Management in Adults With Diabetes
Arauz-Pacheco, C., Parrott, M. A., & Raskin, P. (2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s65 · Cited by 281 · see citing works
Self-citation
European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)
Backer, G. D., Ambrosioni, E., Broch-Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. D., Mancia, G., et al. (2003) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/00149831-200312001-00001 · Cited by 273 · see citing works
Standards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s33 · Cited by 262 · see citing works
Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial
Bakris, G. L., Fonseca, V. A., & Katholi, R. L. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.12.136 · Cited by 254 · see citing works
Prehypertension, Diabetes, and Cardiovascular Disease Risk in a Population-Based Sample
Zhang, Y., Lee, E. T., Devereux, R. B., Yeh, J. L., Best, L. G., Fabsitz, R. R., & Howard, B. V. (2006) · Hypertension · doi:10.1161/01.hyp.0000205119.19804.08 · Cited by 250 · see citing works
“The aims of this observational study are: (1) to estimate the prevalence of prehypertension in a population with a high prevalence of diabetes and (2) to assess hazard ratios for cardiovascular disease with prehypertension in diabetic and nondiabetic individuals.”
Background
Standards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2002) · Diabetes Care · doi:10.2337/diacare.25.1.213 · Cited by 251 · see citing works
The Asheville Project: Short-term outcomes of a community pharmacy diabetes care program
Cranor, C. W., & Christensen, D. B. (2012) · Journal of the American Pharmacists Association · doi:10.1331/japha.2012.12542 · Cited by 238 · see citing works
The Rising Burden of Diabetes and Hypertension in Southeast Asian and African Regions: Need for Effective Strategies for Prevention and Control in Primary Health Care Settings
Mohan, V., Seedat, Y. K., & Pradeepa, R. (2013) · International Journal of Hypertension · doi:10.1155/2013/409083 · Cited by 210 · see citing works
“DM and HTN coexist in approximately 40% to 60% of patients with type 2 DM [46, 47].”
Background
The relationship between glycemic control and platelet activity in type 2 diabetes mellitus
Demirtunç, R., Duman, D., Başar, M., Bilgi, M. M., Teomete, M., & Garip, T. (2008) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2008.01.006 · Cited by 209 · see citing works
“Previous studies have shown that MPV increased in diabetic populations (Arauz-Pacheco et al., 2002; Perkins, Olaleye, Zinman, & Bril, 2001; Sharpe & Trinick, 1993; Winocour, 1994), but this is the first study to evaluate the impact of glycemic control on MPV. DM is a complex syndrome characterized…”
Result
The Asheville Project: Short-Term Outcomes of a Community Pharmacy Diabetes Care Program
Cranor, C. W., & Christensen, D. B. (2003) · Journal of the American Pharmaceutical Association (1996) · doi:10.1331/108658003321480696 · Cited by 206 · see citing works
Treatment blood pressure targets for hypertension
Arguedas, J. A., Perez, M. I., & Wright, J. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004349.pub2 · Cited by 204 · see citing works
Type 1 diabetes, metabolic syndrome and cardiovascular risk
Chillarón, J. J., Flores Le-Roux, J. A., Benaiges, D., & Pedro-Botet, J. (2014) · Metabolism · doi:10.1016/j.metabol.2013.10.002 · Cited by 195 · see citing works
“This would explain why patients with T2DM and those with T1DM and decreased insulin sensitivity maintain low HDL cholesterol levels compared to the general population, even in a normotriglyceridemic situation; however, no specific studies in this group of T1DMpatients are available.”
BackgroundInfluential
Metabolic syndrome pathophysiology: The role of adipose tissue
Laclaustra, M., Corella, D., & Ordovás, J. M. (2007) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2006.10.005 · Cited by 189 · see citing works
Diabetic nephropathy--a review of the natural history, burden, risk factors and treatment.
Ayodele, O. E., Alebiosu, C. O., & Salako, B. L. (2004) · PubMed Central · Cited by 174 · see citing works
The implementation of nutritional advice for people with diabetes
Nutrition Subcommittee of the Diabetes Care Advisory Committee of Diabetes UK (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01104.x · Cited by 171 · see citing works
Interrupting prolonged sitting with brief bouts of light walking or simple resistance activities reduces resting blood pressure and plasma noradrenaline in type 2 diabetes
Dempsey, P. C., Sacre, J. W., Larsen, R. N., Straznicky, N. E., Sethi, P., Cohen, N. D., Cerin, E., Lambert, G. W., Owen, N., Kingwell, B. A., et al. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001101 · Cited by 173 · see citing works
“H ypertension and type 2 diabetes (T2D) are common comorbidities that substantially increase the risk of both microvascular and macrovascular complications [1,2].”
Background
Effects of Telmisartan Compared with Eprosartan on Blood Pressure Control, Glucose Metabolism and Lipid Profile in Hypertensive, Type 2 Diabetic Patients: a Randomized, Double-Blind, Placebo-Controlled 12-Month Study
Derosa, G., Ragonesi, P. D., Mugellini, A., Ciccarelli, L., & Fogari, R. (2004) · Hypertension Research · doi:10.1291/hypres.27.457 · Cited by 169 · see citing works
“5–3 times higher than in non-diabetic age-matched individuals (1).”
European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts).
Backer, G. D., Ambrosio, G., Borch‐Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. D., Mancia, G., et al. (2003) · PubMed · doi:10.1097/01.hjr.0000087913.96265.e2 · Cited by 151 · see citing works
Antihypertensive agents for preventing diabetic kidney disease
Lv, J., Perkovic, V., Foote, C., Craig, M. E., Craig, J. C., & Strippoli, G. F. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004136.pub3 · Cited by 148 · see citing works
Diabetes Mellitus and its Chronic Complications
Bailes, B. K. (2002) · AORN Journal · doi:10.1016/s0001-2092(06)61065-x · Cited by 146 · see citing works
Purification and Identification of antihypertensive peptides in Spanish dry-cured ham
Escudero, E., Mora, L., Fraser, P. D., Aristoy, M., Arihara, K., & Toldrá, F. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.10.019 · Cited by 145 · see citing works
Hypertension Prevalence, Awareness, Treatment, and Control in an Adult Type 1 Diabetes Population and a Comparable General Population
Maahs, D. M., Kinney, G. L., Wadwa, P., Snell‐Bergeon, J. K., Dabelea, D., Hokanson, J. E., Ehrlich, J., Garg, S. K., Eckel, R. H., & Rewers, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.301 · Cited by 138 · see citing works
“Denominator: subjects with hypertension according to JNC or ADA guidelines plus those on antihypertensive medication (numerator for the definition of prevalence).”
BackgroundInfluential
Impact of Overweight on Chronic Microvascular Complications in Type 1 Diabetic Patients
Block, C. E. M. D., Leeuw, I. H. D., & Gaal, L. F. V. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1649 · Cited by 138 · see citing works
Spontaneous Feline Hypertension: Clinical and Echocardiographic Abnormalities, and Survival Rate
Chetboul, V., Lefebvre, H. P., Pinhas, C., Clerc, B., Boussouf, M., & Pouchelon, J. (2003) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2003.tb01328.x · Cited by 131 · see citing works
Prevalence and control of dyslipidemia among persons with diabetes in the United States
Jacobs, M. J., Kleisli, T., Pio, J. R., Malik, S., L'Italien, G. J., Chen, R. S., & Wong, N. D. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.03.032 · Cited by 126 · see citing works
“and women, by ethnicity (African-American, Hispanic, or Caucasian), in comparison to those without diabetes, and by treatment status [28,29].”
Background
Restoring normoglycaemia by use of a very low calorie diet in long‐ and short‐duration Type 2 diabetes
Steven, S., & Taylor, R. (2015) · Diabetic Medicine · doi:10.1111/dme.12722 · Cited by 120 · see citing works
Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension
Umpierrez, G. E., Cantey, P. T., Smiley, D. D., Palacio, A., Temponi, D., Luster, K., & Chapman, A. B. (2007) · Diabetes Care · doi:10.2337/dc07-0031 · Cited by 116 · see citing works
Review: Stroke prevention: modifying risk factors
Romero, J. R., Morris, J. G., & Pikula, A. (2008) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708093847 · Cited by 114 · see citing works
“…if attention is focused on more rigorous control of blood pressure with a goal of <130/80 mm Hg and lipids, with an LDL goal of <100 mg/dl, and treatment with anti-platelet agents, the macrovascular complications of diabetes can be reduced [Arauz-Pacheco et al. 2002; Haffner, 1998; Colwell, 1997].”
Background
The role of nutraceuticals in the prevention of cardiovascular disease
Sosnowska, B., Penson, P. E., & Banach, M. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.03.20 · Cited by 113 · see citing works
“Moreover, patients with diabetes and hypertension have about twice the risk of cardiovascular events as nondiabetic patients with hypertension (83).”
Background
Treatment of Hypertension in Adults With Diabetes
(2002) · Diabetes Care · doi:10.2337/diacare.25.1.199 · Cited by 113 · see citing works
Diabetes and Hypertension: Pathogenesis, Prevention and Treatment
Landsberg, L., & Molitch, M. E. (2004) · Clinical and Experimental Hypertension · doi:10.1081/ceh-200031945 · Cited by 111 · see citing works
The case for low carbohydrate diets in diabetes management
Arora, S. K., & McFarlane, S. I. (2005) · Nutrition & Metabolism · doi:10.1186/1743-7075-2-16 · Cited by 102 · see citing works
“The relationship between hypertension and weight loss is well documented [13,74] and weight loss of 1 kilogram has been reported to decrease mean arterial blood pressure by approximately 1 mm Hg.”
Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain
Orozco‐Beltrán, D., Gil-Guillén, V. F., Quirce, F., Navarro-Perez, J., Pineda, M., de la Cámara, A. G., Pita, S., Díez‐Espino, J., Mateos, J., Merino, J., et al. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01367.x · Cited by 93 · see citing works
A predictive model for cerebrovascular disease using data mining
Yeh, D.-Y., Cheng, C., & Chen, Y. (2011) · Expert Systems with Applications · doi:10.1016/j.eswa.2011.01.114 · Cited by 90 · see citing works
A Structured Educational Program Improves Metabolic Control in Patients With Type 2 Diabetes
Scain, S. F., Friedman, R., & Gross, J. L. (2009) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721709336299 · Cited by 89 · see citing works
High-cocoa polyphenol-rich chocolate improves blood pressure in patients with diabetes and hypertension.
Rostami, A., Khalili, M., Haghighat, N., Eghtesadi, S., Shidfar, F., Heidari, I., Ebrahimpour‐Koujan, S., & Eghtesadi, M. (2015) · Europe PMC (PubMed Central) · Cited by 85 · see citing works
Probiotics and their Effects on Metabolic Diseases: An Update
Aggarwal, J. (2013) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2012/5004.2701 · Cited by 83 · see citing works
Prevalence of Hypertension in Type 2 Diabetes Mellitus: Impact of the Tightening Definition of High Blood Pressure and Association With Confounding Risk Factors
Kabakov, E., Norymberg, C., Osher, E., Koffler, M., Tordjman, K. M., Greenman, Y., & Stern, N. (2006) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4564.2006.05513.x · Cited by 80 · see citing works
Low versus high carbohydrate diet in type 1 diabetes: A 12‐week randomized open‐label crossover study
Schmidt, S., Christensen, M. B., Serifovski, N., Damm‐Frydenberg, C., Jensen, J. B., Fløyel, T., Størling, J., Ranjan, A. G., & Nørgaard, K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13725 · Cited by 77 · see citing works
“4) kg/m(2), diabetes duration 19 (13-32) years, HbA1c 58 (55-60) mmol/mol [7.”
Antihypertensive Agents for Primary Prevention of Diabetic Nephropathy
Strippoli, G. F., Craig, M. E., Schena, F. P., & Craig, J. C. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080634 · Cited by 78 · see citing works
Hypertension and Diabetes
Grossman, E., & Messerli, F. H. (2008) · KARGER eBooks · doi:10.1159/000115189 · Cited by 76 · see citing works
Effect of Losartan on Microalbuminuria in Normotensive Patients with Type 2 Diabetes Mellitus
Zandbergen, A. A. M., Baggen, M. G. A., Lamberts, S. W. J., Bootsma, A. H., de Zeeuw, D., & Ouwendijk, R. J. T. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00008 · Cited by 73 · see citing works
“The current definition of normotension is a blood pressure less than 140/90 mm Hg, with a blood pressure– lowering target of less than 130/80 mm Hg in hypertensive adults with diabetes mellitus (25, 26); however, we developed the protocol for this study in 1998, when normotension was defined as a sitting blood pressur…”
Diabetes and cardiovascular disease: inter-relation of risk factors and treatment
Sharma, A., Mittal, S., Aggarwal, R., & Chauhan, M. K. (2020) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-020-00151-w · Cited by 71 · see citing works
“in a clinical trial, the sodium intake was reduced from 4600mg to 2300mg [175] -Reduced pressure of blood (systolic approx.”
Background
Diabetes knowledge and glycemic control among Chinese people with type 2 diabetes
He, X., & Wharrad, H. J. (2007) · International Nursing Review · doi:10.1111/j.1466-7657.2007.00570.x · Cited by 65 · see citing works
Purification of a Novel Angiotensin I-Converting Enzyme (ACE) Inhibitory Peptide with an Antihypertensive Effect from Loach (Misgurnus anguillicaudatus)
Li, Y., Zhou, J., Huang, K., Sun, Y., & Zeng, X. (2012) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf204118n · Cited by 61 · see citing works
Prevalence, awareness, treatment and control of hypertension in Galicia (Spain) and association with related diseases
Pérez-Fernández, R., Mariño, A. F., Cadarso-Suárez, C., Botana, M., Tomé, M. A., Solache, I., Iraeta, A. R., & Mato, A. (2007) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002158 · Cited by 60 · see citing works
Potassium, Calcium, Magnesium, and Sodium Levels in Biological Samples of Hypertensive and Nonhypertensive Diabetes Mellitus Patients
Afridi, H. I., Kazi, T. G., Kazi, N. G., Jamali, M. K., Arain, M. B., Jalbani, N. B., Sarfraz, R. A., Shah, A., Kandhro, G. A., Shah, A. Q., et al. (2008) · Biological Trace Element Research · doi:10.1007/s12011-008-8142-7 · Cited by 59 · see citing works
“Furthermore, it has been clearly shown that hypertension in diabetic patients is associated with accelerated progression of both microvascular (retinopathy and nephropathy) and macrovascular (atherosclerotic) complications [5].”
Background
Antihypertensive agents for preventing diabetic kidney disease
Strippoli, G. F., Craig, M. E., Craig, J. C., Lv, J., & Perkovic, V. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004136.pub2 · Cited by 59 · see citing works
Early atherosclerosis in childhood type 1 diabetes: role of raised systolic blood pressure in the absence of dyslipidaemia
Schwab, K. O., Doerfer, J., Krebs, A., Krebs, K., Schorb, E., Hallermann, K., Superti‐Furga, A., Zieger, B., März, W., Schmidt‐Trucksäss, A., et al. (2007) · European Journal of Pediatrics · doi:10.1007/s00431-007-0440-0 · Cited by 53 · see citing works
“About one third of type 1 diabetic adults may develop hypertension with advancing duration of diabetes [2].”
Background
Blood Pressure Control and Pharmacotherapy Patterns in the United States Before and After the Release of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) Guidelines
Jackson, J. H., Sobolski, J. C., Krienke, R., Wong, K. S., Frech‐Tamas, F., & Nightengale, B. S. (2008) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2008.06.080025 · Cited by 53 · see citing works
“Because hypertension is a precursor to multiple disease conditions, maintaining blood pressure (BP) control and adherence to goals are imperative to reducing morbidity and mortality, especially in patients with high risk.(2,3) Since its first report in 1977, the Joint National Committee on the Prevention, Detection, E…”
Background
Macrovascular angiopathy in children and adolescents with type 1 diabetes
Giannini, C., Mohn, A., Chiarelli, F., & Kelnar, C. J. H. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1195 · Cited by 52 · see citing works
Treatment of Hypertension in Adults With Diabetes
American Diabetes Association (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s71 · Cited by 50 · see citing works
Formulation and design optimization of nano-transferosomes using pioglitazone and eprosartan mesylate for concomitant therapy against diabetes and hypertension
Ramkanth, S., Anitha, P., Gayathri, R., Mohan, S., & Babu, D. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105811 · Cited by 49 · see citing works
Lifestyle Modification to Improve Blood Pressure Control in Individuals With Diabetes
Egede, L. E. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.602 · Cited by 49 · see citing works
“Nearly 60% of adults with diabetes have comorbid hypertension (4,5), and data suggest that when diabetes and hypertension coexist, the risk for cardiovascular events doubles (6).”
Background
Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats
Goyal, B. R., Mesariya, P., Goyal, R. K., & Mehta, A. A. (2008) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-9772-y · Cited by 48 · see citing works
“Hypertension is an extremely common comorbid condition affecting approximately 20–60% of patients with diabetes, depending on obesity, ethnicity, and age [3].”
Background
Association of glycosylated haemoglobin level and diabetes mellitus duration with the severity of coronary artery disease
Saleem, T., Mohammad, K. H., Abdel-Fattah, M. M., & Abbasi, A. H. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.030 · Cited by 46 · see citing works
Effects of guided breathing on blood pressure and heart rate variability in hypertensive diabetic patients
Howorka, K., Pumprla, J., Tamm, J., Schabmann, A., Klomfar, S., Kostineak, E., Howorka, N., & Sovová, E. (2013) · Autonomic Neuroscience · doi:10.1016/j.autneu.2013.08.065 · Cited by 44 · see citing works
Insulin resistance and hypertension in patients with type 1 diabetes
Chillarón, J. J., Sales, M. P., Roux, J. A. F., Murillo, J., Benaiges, D., Castells, I., Goday, A., Cano-Pérez, J. F., & Pedro‐Botet, J. (2011) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2011.03.006 · Cited by 44 · see citing works
Metabolic Syndrome Pathophysiology
Das, U. N. (2010) · Wiley eBooks · doi:10.1002/9780813820637 · Cited by 44 · see citing works
An evaluation of the impact of antidiabetic medication on treatment satisfaction and quality of life in patients of diabetes mellitus
Desai, C. K., Chaturvedi, R., Patel, P., Shah, A. N., & Dikshit, R. (2018) · Perspectives in Clinical Research · doi:10.4103/picr.picr_140_16 · Cited by 43 · see citing works
“Diabetes and HT coexist in approximately 40%–60% of patients with type 2 diabetes.[17,18] Sixty‐five percent patients had a relative or sibling who also suffered from DM.”
Background
The prevalence of pre-diabetes and diabetes and their associated factors in Northeast China: a cross-sectional study
Wang, R., Zhang, P., Li, Z., Lv, X., Cai, H., Gao, C., Song, Y., Yu, Y., Li, B., & Cui, Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-39221-2 · Cited by 43 · see citing works
TREATMENT OF TYPE 2 DIABETES
Scheen, A. J. (2003) · Acta Clinica Belgica · doi:10.1179/acb.2003.58.5.010 · Cited by 42 · see citing works
“Adequate treatment of hypertension has acquired a major importance in the overall management of individuals with type 2 diabetes (24).”
Background
Endothelial dysfunction and hypertension in diabetes mellitus
Dandona, P., Chaudhuri, A., & Aljada, A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.006 · Cited by 40 · see citing works
Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations
Giles, T. D., & Sander, G. E. (2004) · Cardiology Clinics · doi:10.1016/j.ccl.2004.07.002 · Cited by 41 · see citing works
“The ADA, the National Kidney Foundation, and JNC VII advocate lowering blood pressure to less than 130/80 mm Hg in patients who have diabetes mellitus [116–118].”
Background
Pharmacologic management of hypertension in patients with diabetes.
Whalen, K., & Stewart, R. D. (2008) · PubMed · Cited by 41 · see citing works
Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension
Chrysant, S. G., Lee, J., Melino, M. R., Karki, S., & Heyrman, R. (2010) · Journal of Human Hypertension · doi:10.1038/jhh.2010.5 · Cited by 40 · see citing works
Management of Blood Pressure in Patients With Diabetes
Grossman, E., & Messerli, F. H. (2011) · American Journal of Hypertension · doi:10.1038/ajh.2011.77 · Cited by 40 · see citing works
Undiagnosed hypertension in a rural district in Bangladesh: The Bangladesh Population-based Diabetes and Eye Study (BPDES)
Islam, A. F. M., Bhuiyan, A., Chakrabarti, R., Rahman, M. A., Kanagasingam, Y., & Hiller, J. E. (2015) · Journal of Human Hypertension · doi:10.1038/jhh.2015.65 · Cited by 39 · see citing works
Técnicas educacionales en el tratamiento de la diabetes
Selli, L., Papaléo, L. K., Meneghel, S. N., & Torneros, J. Z. (2005) · Cadernos de Saúde Pública · doi:10.1590/s0102-311x2005000500008 · Cited by 38 · see citing works
Management of diabetic hypertensives
Viswanathan, V., & Ganesh, J. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.86982 · Cited by 38 · see citing works
“From various studies and guidelines, the following are observed:[58,59]”
Background
Acute Decompensated Heart Failure: A Contemporary Approach to Pharmacotherapeutic Management
McBride, B. F., & White, C. M. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.8.997.32873 · Cited by 37 · see citing works
Study of drug utilization pattern of antihyperglycemic agents in a South Indian tertiary care teaching hospital
Churi, S., Abdi, S. A. H., & Kumar, Y. R. (2012) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.93850 · Cited by 36 · see citing works
“[13] Prescribing Pattern of AHA The average number of antidiabetic drugs per prescription was 0.94 which is less than 2.27 of that previously recorded in India.”
Influential
Cardiovascular disease risk in youth with diabetes mellitus
Wadwa, R. P. (2006) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-006-9016-y · Cited by 36 · see citing works
“Angiotensin receptor blockers have been used in adults with diabetes [41], however, there are no data available for the use of these agents in children with diabetes at this time.”
Background
Masked hypertension, nocturnal blood pressure and retinopathy in normotensive patients with type 1 diabetes
Rodrigues, T. D. C., Canani, L. H. S., Viatroski, R. S., Hoffmann, L. H., Esteves, J., & Gross, J. L. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.016 · Cited by 35 · see citing works
“Hypertension has been estimated to affect 30–43% of type 1 diabetic patients and usually appears after the development of diabetic nephropathy (DN) [1].”
Background
A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus
Derosa, G., Cicero, A. F. G., Ciccarelli, L., & Fogari, R. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80201-1 · Cited by 35 · see citing works
Improving Efficacy of Diabetes Management Using Treatment Algorithms in a Mainly Hispanic Population
Fanning, E. L., Selwyn, B. J., Larme, A. C., & DeFronzo, R. A. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1638 · Cited by 35 · see citing works
Treatment of Hypertension in Adults With Diabetes
Raskin, P. (2003) · Clinical Diabetes · doi:10.2337/diaclin.21.3.120 · Cited by 34 · see citing works
Self-citation
Investigation of mean platelet volume in patients with type 2 diabetes mellitus and in subjects with impaired fasting glucose: a cost-effective tool in primary health care?
Özder, A., & Eker, H. H. (2014) · Europe PMC (PubMed Central) · Cited by 33 · see citing works
Sera from Patients with Type 2 Diabetes Contain Agonistic Autoantibodies Against G Protein‐Coupled Receptors
Hempel, P., Karczewski, P., Kohnert, K. ‐., Raabe, J., Lemke, B., Kunze, R., & Bimmler, M. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02280.x · Cited by 33 · see citing works
Prevalence, risk factors, and management of uncontrolled hypertension among patients with diabetes: A hospital-based cross-sectional study
Almalki, Z. S., Albassam, A. A., Alhejji, N. S., Alotaibi, B. S., Al-Oqayli, L. A., & Ahmed, N. J. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.02.004 · Cited by 32 · see citing works
Heart Failure in Diabetes and Related Conditions
Kamalesh, M. (2007) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2007.07.007 · Cited by 32 · see citing works
Stroke prevention in diabetes and obesity
Kurukulasuriya, L. R., Govindarajan, G., & Sowers, J. R. (2006) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.4.4.487 · Cited by 30 · see citing works
Prevalence of Hyperuricemia in Indian Subjects attending Hyperuricemia Screening Programs-A Retrospective Study.
Billa, G., Dargad, R. R., & Mehta, A. (2018) · PubMed · Cited by 30 · see citing works

Clinical observation of the serum uric acid level in the elderly with hypertension complicated with diabetes
Liu, C. (2007) · Shiyong laonian yixue
Urinary Transforming Growth Factor- Excretion in Patients With Hypertension, Type 2 Diabetes, and Elevated Albumin
Houlihan, C. A., Akdeniz, A., Cooper, M. E., Jerums, G., & Gilbert, R. E. (2002)
THE ASSOCIATION OF EGFR AND ALBUMINURIA WITH SYSTOLIC HYPERTENSION IN PATIENTS WITH DIABETES
Georgianou, E., Markakis, K., Georgianos, P. I., Zografou, I., Sachinidis, A. G., Sabanis, C., & Doumas, M. N. (2022) · Journal of Hypertension · doi:10.1097/01.hjh.0000837388.45297.ab
Ambulatory blood pressure and urinary albumin excretion in diabetic (non–insulin-dependent and insulin-dependent) hypertensive patients Relationships at baseline and after treatment by the angiotensin converting enzyme inhibitor trandolapril
Bauduceau, B., Genès, N., Chamontin, B., Vaur, L., RENAULT, M., Etienne, S., & Marre, M. (1998) · American Journal of Hypertension · doi:10.1016/s0895-7061(98)00118-6 · Cited by 18 · see citing works
Management of hypertension in elderly diabetic patients
Blicklé, J. F. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(05)73656-9 · Cited by 12 · see citing works

Authors: Arauz-Pacheco, C., Parrott, M. A., & Raskin, P.
Affiliations: George Washington University (US)
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2002-01-01
Volume: 25
Issue: 1
Pages: 134-147
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/diacare.25.1.134
OpenAlex: W2138299277
Cited by: 326
References: 129
Citations by year: 2026: 2 · 2025: 1 · 2024: 5 · 2023: 5 · 2022: 4 · 2021: 7 · 2020: 11 · 2019: 8 · 2018: 4 · 2017: 14 · 2016: 14 · 2015: 15 · 2014: 16 · 2013: 12 · 2012: 19
FWCI: 4.04
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: hypertension, diabetes mellitus, antihypertensive therapy, blood pressure control, diabetic nephropathy, diabetic retinopathy, cardiovascular complications, microvascular complications, antihypertensive drug classes
MeSH terms: Adult, Diabetic Angiopathies, Female, Humans, Hypertension, Lactation, Pregnancy, Pregnancy in Diabetics, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Treatment of Hypertension in Adult Patients With Diabetes

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks